Literature DB >> 35617919

The CD8α hinge is intrinsically disordered with a dynamic exchange that includes proline cis-trans isomerization.

Xiang Chen1, Justin M Mirazee2, Katarzyna A Skorupka3, Hiroshi Matsuo3, Philippe Youkharibache4, Naomi Taylor5, Kylie J Walters6.   

Abstract

T cells engineered to express artificial chimeric antigen receptors (CARs) that selectively target tumor-specific antigens or deleterious cell types offer transformative therapeutic possibilities. CARs contain an N-terminal extracellular antigen recognition domain, C-terminal intracellular signal transduction domains, and connecting hinge and transmembrane regions, each of which have been varied to optimize targeting and minimize toxicity. We find that a CD22-targeting CAR harboring a CD8α hinge (H) exhibits greater cytotoxicity against a low antigen density CD22+ leukemia as compared to an equivalent CAR with a CD28 H. We therefore studied the biophysical and dynamic properties of the CD8α H by nuclear magnetic resonance (NMR) spectroscopy. We find that a large region of the CD8α H undergoes dynamic chemical exchange between distinct and observable states. This exchanging region contains proline residues dispersed throughout the sequence that undergo cis-trans isomerization. Up to four signals of differing intensity are observed, with the most abundantly populated being intrinsically disordered and with all prolines in the trans isomerization state. The lesser populated states all contain cis prolines and evidence of local structural motifs. Altogether, our data suggest that the CD8α H lacks long-range structural order but has local structural motifs that transiently exchange with a dominant disordered state. We propose that structural plasticity and local structural motifs promoted by cis proline states within the CD8α H are important for relaying and amplifying antigen-binding effects to the transmembrane and signal transduction domains. Published by Elsevier Inc.

Entities:  

Keywords:  CAR T-cell; CD8; Intrinsically disordered proteins; Linker; Proline isomerization

Mesh:

Substances:

Year:  2022        PMID: 35617919      PMCID: PMC9237829          DOI: 10.1016/j.jmr.2022.107234

Source DB:  PubMed          Journal:  J Magn Reson        ISSN: 1090-7807            Impact factor:   2.734


  74 in total

1.  Random coil chemical shifts in acidic 8 M urea: implementation of random coil shift data in NMRView.

Authors:  S Schwarzinger; G J Kroon; T R Foss; P E Wright; H J Dyson
Journal:  J Biomol NMR       Date:  2000-09       Impact factor: 2.835

2.  Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.

Authors:  Sneha Ramakrishna; Steven L Highfill; Zachary Walsh; Sang M Nguyen; Haiyan Lei; Jack F Shern; Haiying Qin; Ira L Kraft; Maryalice Stetler-Stevenson; Constance M Yuan; Jennifer D Hwang; Yang Feng; Zhongyu Zhu; Dimiter Dimitrov; Nirali N Shah; Terry J Fry
Journal:  Clin Cancer Res       Date:  2019-05-20       Impact factor: 12.531

3.  A zinc clasp structure tethers Lck to T cell coreceptors CD4 and CD8.

Authors:  Peter W Kim; Zhen-Yu J Sun; Stephen C Blacklow; Gerhard Wagner; Michael J Eck
Journal:  Science       Date:  2003-09-19       Impact factor: 47.728

4.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

Authors:  Carmine Carpenito; Michael C Milone; Raffit Hassan; Jacqueline C Simonet; Mehdi Lakhal; Megan M Suhoski; Angel Varela-Rohena; Kathleen M Haines; Daniel F Heitjan; Steven M Albelda; Richard G Carroll; James L Riley; Ira Pastan; Carl H June
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-11       Impact factor: 11.205

5.  Toll-like receptor 3 transmembrane domain is able to perform various homotypic interactions: an NMR structural study.

Authors:  Konstantin S Mineev; Sergey A Goncharuk; Alexander S Arseniev
Journal:  FEBS Lett       Date:  2014-09-12       Impact factor: 4.124

6.  FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia.

Authors:  Maura C O'Leary; Xiaobin Lu; Ying Huang; Xue Lin; Iftekhar Mahmood; Donna Przepiorka; Denise Gavin; Shiowjen Lee; Ke Liu; Bindu George; Wilson Bryan; Marc R Theoret; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2018-10-11       Impact factor: 12.531

7.  Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.

Authors:  Carlos A Ramos; Natalie S Grover; Anne W Beaven; Premal D Lulla; Meng-Fen Wu; Anastasia Ivanova; Tao Wang; Thomas C Shea; Cliona M Rooney; Christopher Dittus; Steven I Park; Adrian P Gee; Paul W Eldridge; Kathryn L McKay; Birju Mehta; Catherine J Cheng; Faith B Buchanan; Bambi J Grilley; Kaitlin Morrison; Malcolm K Brenner; Jonathan S Serody; Gianpietro Dotti; Helen E Heslop; Barbara Savoldo
Journal:  J Clin Oncol       Date:  2020-07-23       Impact factor: 50.717

8.  Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22.

Authors:  Haiying Qin; Sneha Ramakrishna; Sang Nguyen; Thomas J Fountaine; Anusha Ponduri; Maryalice Stetler-Stevenson; Constance M Yuan; Waleed Haso; Jack F Shern; Nirali N Shah; Terry J Fry
Journal:  Mol Ther Oncolytics       Date:  2018-11-06       Impact factor: 7.200

9.  Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.

Authors:  Gils Roex; Marijke Timmers; Kristien Wouters; Diana Campillo-Davo; Donovan Flumens; Wilfried Schroyens; Yiwei Chu; Zwi N Berneman; Eva Lion; Feifei Luo; Sébastien Anguille
Journal:  J Hematol Oncol       Date:  2020-12-03       Impact factor: 17.388

Review 10.  The alphabet of intrinsic disorder: I. Act like a Pro: On the abundance and roles of proline residues in intrinsically disordered proteins.

Authors:  Francois-Xavier Theillet; Lajos Kalmar; Peter Tompa; Kyou-Hoon Han; Philipp Selenko; A Keith Dunker; Gary W Daughdrill; Vladimir N Uversky
Journal:  Intrinsically Disord Proteins       Date:  2013-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.